NEW YORK, May 21, 2026, 12:08 (EDT)
- COCP was at $1.11 on Nasdaq, down a penny, with light volume late in the morning in New York.
- Cocrystal’s next hurdle for the stock is on the clinical side. Investors are looking to the Phase 1b norovirus challenge study now, not to macro factors.
- The latest quarterly filing from the company pointed to tight cash and a going-concern alert.
Cocrystal Pharma fell to $1.11 in thin volume Thursday as the market looked for new updates from the company’s norovirus drug work. Shares changed hands between $1.09 and $1.11. The SPDR S&P Biotech ETF was also a touch lower.
COCP’s move is notable. The stock trades as a micro-cap, with its market value at about $15.3 million as of the latest quote. Fewer than 20,000 shares traded, so small orders can swing the price sharply and old news can hit harder.
Cocrystal Pharma’s most recent investor update is still its first-quarter report from May 15. The company said it wrapped up enrollment in the first group of its Phase 1b human challenge study for CDI-988, an oral candidate for norovirus, while also starting enrollment for the prevention and treatment groups. Human challenge studies involve giving healthy people a pathogen in a controlled setting to see if a drug is effective.
Cocrystal president and co-CEO Sam Lee said the move is a “pivotal milestone.” Lee said the study format will let the company test CDI-988 for prevention and as a treatment.
Bullish arguments here focus on CDI-988. There’s no approved treatment or vaccine for norovirus, and Cocrystal says its drug is a direct-acting antiviral designed to block the virus, not just manage symptoms. The FDA granted Fast Track to CDI-988, a status meant to speed up the agency’s review of experimental drugs for serious conditions lacking good treatments.
Cocrystal’s Lee told an antiviral research event in late April the drug might offer a “much-needed option” as an oral therapy that could be stockpiled ahead of outbreaks. The company reported its Phase 1 trial in healthy adults showed CDI-988 was generally safe and well tolerated up to 1,200 mg, with headache reported most often as a treatment-emergent side effect. Cocrystal Pharma
Cocrystal’s 10-Q showed a tighter balance sheet. Cash stood at $4.7 million on March 31, down from $7.0 million at the end of December. The company posted a first-quarter net loss of $2.3 million, or 17 cents a share. The filing flagged “substantial doubt” about Cocrystal’s ability to keep operating, a standard warning that the company might need more funding.
Cocrystal brought in outside backing. James Martin, the CFO and co-CEO, said the company got “non-dilutive funding” from an NIH small-business grant for its influenza A and B projects. Non-dilutive funding is money that doesn’t involve selling more shares.
The outlook for competition is mixed. Moderna has mRNA-1403 in Phase 3 and mRNA-1405 in Phase 2. Vaxart in March said it had published Phase 1 results in lactating women for its oral bivalent norovirus vaccine and plans to look for a partner or other funding for its next norovirus trial in 2026.
Investors have already taken hits in this space. HilleVax scrapped its infant norovirus vaccine program after a failed mid-stage trial in 2024. Reuters noted that Moderna and Vaxart had their own vaccine efforts. Leerink Partners’ David Risinger said back then there could still be interest in adult vaccines, since adults are usually exposed to norovirus before.
Zacks Small Cap Research analyst David Bautz said in February that Cocrystal’s ongoing challenge study could hit an “important inflection point” in late 2026 or early 2027 if results are positive. Zacks noted it receives compensation for covering the issuer, something investors typically consider when looking at sponsored small-cap research. Zacks
COCP faces clear risk. If the challenge study misses a clear signal, if enrollment dips, or if the company can’t get funding on good terms, the stock may drop fast. On Thursday, COCP is trading more on tape action than any looming clinical news.
